Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rebif® Clear all
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS

NCT04032171
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

NCT00548405
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
85
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

NCT01119677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Avonex
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
31
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Avonex 15 Year Long Term Follow-up Study

NCT00525343
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Buffalo, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Results available

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

NCT02019550
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Rebif Rebidose, Rebiject II
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Cullman, Alabama • Tuscon, Arizona • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Results available

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif®, Copaxone®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 24, 2026, 4:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

NCT00391352
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Results available

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

NCT02269930
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
peginterferon beta-1a, Rebif
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 24, 2026, 4:08 PM EDT
Completed No phase listed Observational Results available

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

NCT01207648
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
Up to 18 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
Device · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated No phase listed Observational

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

NCT01156298
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Sep 24, 2026, 4:08 PM EDT
Withdrawn Phase 4 Interventional

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115
View directory record Official record
Conditions
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions
interferon beta 1a, methotrexate, methylprednisolone
Drug
Lead sponsor
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

NCT00616434
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
BG9418 (Interferon beta-1a), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Lakewood, Colorado • Bristol, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2009 · Synced Sep 24, 2026, 4:08 PM EDT
Completed No phase listed Observational Results available

Rebif® Pregnancy Registry

NCT00338741
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

RNF and Betaseron® Tolerability Study

NCT00428584
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

NCT02047734
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Ozanimod placebo, Interferon beta-1a, Interferon beta-1a placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 24, 2026, 4:08 PM EDT